×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BYSI – beyondspring, inc. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BYSI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
07:39 am
bysi
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path [Yahoo! Finance]
Medium
Report
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path [Yahoo! Finance]
12/12
07:00 am
bysi
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
Medium
Report
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
12/11
07:31 am
bysi
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 [Yahoo! Finance]
Neutral
Report
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 [Yahoo! Finance]
12/11
07:00 am
bysi
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
Medium
Report
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
11/12
08:19 am
bysi
BeyondSpring GAAP EPS of -$0.05 [Seeking Alpha]
Medium
Report
BeyondSpring GAAP EPS of -$0.05 [Seeking Alpha]
11/12
07:00 am
bysi
BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update
10/8
12:15 pm
bysi
BeyondSpring (NASDAQ:BYSI) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
BeyondSpring (NASDAQ:BYSI) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:30 pm
bysi
Form 8-K BeyondSpring Inc. For: Nov 17
Low
Report
Form 8-K BeyondSpring Inc. For: Nov 17
11/12
04:31 pm
bysi
Form 10-Q BeyondSpring Inc. For: Sep 30
Low
Report
Form 10-Q BeyondSpring Inc. For: Sep 30
11/12
07:01 am
bysi
Form 8-K BeyondSpring Inc. For: Nov 12
Medium
Report
Form 8-K BeyondSpring Inc. For: Nov 12
10/20
08:00 pm
bysi
Form 4 BeyondSpring Inc. For: Oct 16 Filed by: Cui Xiangmin
High
Report
Form 4 BeyondSpring Inc. For: Oct 16 Filed by: Cui Xiangmin
10/15
08:07 pm
bysi
Form 4 BeyondSpring Inc. For: Oct 13 Filed by: Cui Xiangmin
High
Report
Form 4 BeyondSpring Inc. For: Oct 13 Filed by: Cui Xiangmin
10/10
05:58 pm
bysi
Form 4 BeyondSpring Inc. For: Oct 08 Filed by: Decheng Capital Global Healthcare Fund (Master), LP
Low
Report
Form 4 BeyondSpring Inc. For: Oct 08 Filed by: Decheng Capital Global Healthcare Fund (Master), LP
10/7
06:15 pm
bysi
Form 4 BeyondSpring Inc. For: Oct 03 Filed by: Decheng Capital Global Healthcare Fund (Master), LP
Neutral
Report
Form 4 BeyondSpring Inc. For: Oct 03 Filed by: Decheng Capital Global Healthcare Fund (Master), LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Beyondspring Inc (NASDAQ: BYSI) had its "buy" rating re-affirmed by analysts at William Blair.
22.2%
9/6 BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference 19.2%
4/28 Beyondspring Inc (NASDAQ: BYSI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.8%
1/10 Beyondspring Inc (NASDAQ: BYSI) is now covered by analysts at Nomura. They set a "buy" rating and a $34.00 price target on the stock. 11.3%
12/9 BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting 4.4%
9/10 BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer 4.3%
5/16 BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting 4.2%
12/19 BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies 3.4%
10/23 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock. 3.1%
9/11 BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019 2.7%
9/6 BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference 19.2%
4/28 Beyondspring Inc (NASDAQ: BYSI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.8%
1/10 Beyondspring Inc (NASDAQ: BYSI) is now covered by analysts at Nomura. They set a "buy" rating and a $34.00 price target on the stock. 11.3%
12/9 BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting 4.4%
9/10 BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer 4.3%
5/16 BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting 4.2%
12/19 BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies 3.4%
10/23 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock. 3.1%
9/11 BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019 2.7%
TOP News Decliners
10/24
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
-26.8%
2/10 BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients -19.4%
7/16 BeyondSpring Announces Proposed Public Offering of Ordinary Shares -10.4%
3/11 Form 6-K BeyondSpring Inc. For: Mar 11 -8.7%
4/30 Form 20-F BeyondSpring Inc. For: Dec 31 -8.6%
3/11 BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 -8.1%
5/21 Form 424B5 BeyondSpring Inc. -6.8%
4/20 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -6.1%
10/23 BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia -5.2%
8/23 BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia -5.0%
2/10 BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients -19.4%
7/16 BeyondSpring Announces Proposed Public Offering of Ordinary Shares -10.4%
3/11 Form 6-K BeyondSpring Inc. For: Mar 11 -8.7%
4/30 Form 20-F BeyondSpring Inc. For: Dec 31 -8.6%
3/11 BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 -8.1%
5/21 Form 424B5 BeyondSpring Inc. -6.8%
4/20 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -6.1%
10/23 BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia -5.2%
8/23 BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: